sales@angenesci.com
Login | Register
logo
Structures Search
Home Other Building Blocks 4'-C-Azidocytidine 2',3',5'-tris(2-methylpropanoate)

4'-C-Azidocytidine 2',3',5'-tris(2-methylpropanoate)

CAS No.:
690270-29-2
Catalog Number:
AG00FBZD
Molecular Formula:
C21H30N6O8
Molecular Weight:
494.4983
Pack Size
Purity
Availability
Location
Price(USD)
Quantity
  
5mg
97%
1 week
United States
$390
- +
10mg
97%
1 week
United States
$607
- +
50mg
97%
1 week
United States
$1723
- +
Product Description
Catalog Number:
AG00FBZD
Chemical Name:
4'-C-Azidocytidine 2',3',5'-tris(2-methylpropanoate)
CAS Number:
690270-29-2
Molecular Formula:
C21H30N6O8
Molecular Weight:
494.4983
MDL Number:
MFCD18251433
IUPAC Name:
[(2R,3S,4R,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-2-azido-3,4-bis(2-methylpropanoyloxy)oxolan-2-yl]methyl 2-methylpropanoate
InChI:
InChI=1S/C21H30N6O8/c1-10(2)17(28)32-9-21(25-26-23)15(34-19(30)12(5)6)14(33-18(29)11(3)4)16(35-21)27-8-7-13(22)24-20(27)31/h7-8,10-12,14-16H,9H2,1-6H3,(H2,22,24,31)/t14-,15+,16-,21-/m1/s1
InChI Key:
VKXWOLCNTHXCLF-DXEZIKHYSA-N
SMILES:
[N-]=[N+]=N[C@]1(COC(=O)C(C)C)O[C@H]([C@@H]([C@@H]1OC(=O)C(C)C)OC(=O)C(C)C)n1ccc(nc1=O)N
UNII:
VOT0LP7I9K
Properties
Complexity:
971  
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1  
Defined Atom Stereocenter Count:
4  
Defined Bond Stereocenter Count:
0
Exact Mass:
494.213g/mol
Formal Charge:
0
Heavy Atom Count:
35  
Hydrogen Bond Acceptor Count:
10  
Hydrogen Bond Donor Count:
1  
Isotope Atom Count:
0
Molecular Weight:
494.505g/mol
Monoisotopic Mass:
494.213g/mol
Rotatable Bond Count:
12  
Topological Polar Surface Area:
161A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
1  
XLogP3:
2.5  
Literature
Title Journal
Chemical stability of 4'-azidocytidine and its prodrug balapiravir. Drug development and industrial pharmacy 20100401
Phosphoramidate prodrugs of 2'-C-methylcytidine for therapy of hepatitis C virus infection. Journal of medicinal chemistry 20090910
Robust antiviral activity of R1626, a novel nucleoside analog: a randomized, placebo-controlled study in patients with chronic hepatitis C. Hepatology (Baltimore, Md.) 20080801
R1626 plus peginterferon Alfa-2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin. Hepatology (Baltimore, Md.) 20080801
Physicochemical properties of the nucleoside prodrug R1626 leading to high oral bioavailability. Drug development and industrial pharmacy 20080701
The hepatitis C virus replicon presents a higher barrier to resistance to nucleoside analogs than to nonnucleoside polymerase or protease inhibitors. Antimicrobial agents and chemotherapy 20080501
Future treatment options for HCV: double, triple, what is the optimal combination? Best practice & research. Clinical gastroenterology 20080101
Properties